CSF2 and urinary bladder neoplasm: Given the rarity of G-/GM-CSF-secreting bladder tumors and an increasing use of recombinant G-/GM-CSF, appropriate diagnostic approaches are needed to identify patients to whom such therapies may be detrimental 60–62.